$ARDX

RAAB MICHAEL sold $226K of ARDX

RAAB MICHAEL (President & CEO) sold 58,574 shares of ARDELYX, INC. (ARDX) at $3.86 ($0.23M total) across 4 trades on 2026-08-21.

Original reporting
SEC EDGAR · RAAB MICHAEL
Published Aug 25, 2026, 11:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 11:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARDX
Bearish
medium confidence
Mentioned
$ARDX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARDXBearishLow
01

Why it matters

The filing provides the first public record of the CEO's share sale, offering a data point for investors.

02

Market read

Insider sale by the CEO may influence short‑term sentiment but is unlikely to drive major price movement.

03

What to watch

The CEO retains a large stake (over 1.6M shares) and may be diversifying without losing confidence.

Relevance 4/10Novelty 5/10Timing: post‑market filing on 2026‑08‑25

Background

Form 4 filing discloses insider transactions required by the SEC.

Company-level read

Ticker impact

$ARDXBearishMedium confidence
Context

CEO Michael Raab sold 58,574 shares for $225,914 on 2026-08-21.

Expected impact

Potential short‑term pressure on ARDX, modest downside of 1‑2% if market reacts.

Evidence & confidence

The sale size is modest ($226K) relative to holdings, but CEO involvement gives weight to the signal.

Market effects

Minimal impact on the broader biotech sector; insider sales are common and not sector‑wide.

No significant regional effect; the company trades primarily on US exchanges.

Limited global relevance beyond ARDX shareholders.

Counterpoint

The sale could be routine liquidity management rather than a negative signal.

Key entities

  • Michael Raab

    President & CEO of ArdeLynx, Inc.

  • ArdeLynx, Inc.

    Biotech firm listed on NASDAQ under ticker ARDX.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARDXMedAI 8/10

Ardelyx (ARDX) Q2 2026 Earnings Call Transcript

Ardelyx (ARDX) reported Q2 2026 product revenue of $118.1 million, up 31% year over year, driven by IBSRELA ($86.2 million, +33%) and XPHOZAH ($31.9 million, +27%). Net loss was $16.7 million. The company revised 2026 guidance to $350-$370 million for IBSRELA and $110-$120 million for XPHOZAH, citing payer hurdles.

$ARDXHighAI 9/10

Why is Ardelyx stock plunging today?

Ardelyx (ARDX) shares fell about 16% pre-open after the company reported Q2 2026 results that missed Wall Street on revenue and EPS and cut full-year guidance. Q2 total product revenue was $118.1M, net loss $16.7M (-$0.07/share). Ardelyx lowered 2026 IBSRELA revenue guidance to $350–$370M and withdrew a prior XPHOZAH long-term target.

$ARDXMed

ARDELYX, INC. (ARDX): Results of Operations and Financial Condition

ARDELYX, INC. (ARDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update Q2 2026 total product revenue of $118.1 million, reflecting 31% growth year-over-year IBSRELA Q2 2026 revenue growth of 33% year-over-year to $86.2 million XPHOZAH Q2 2026 revenue grow